Squarepoint
TNGX icon

Squarepoint’s Tango Therapeutics TNGX Stock Holding History

Squarepoint’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74M Buy
178,915
+4,979
+3% +$69.3K ﹤0.01% 1725
2025
Q4 		$1.54M Buy
+173,936
New +$1.5M ﹤0.01% 2246
2025
Q1 		– Sell
-12,843
Closed -$39.7K – 5419
2024
Q4 		$39.7K Buy
+12,843
New +$59.6K ﹤0.01% 4877
2024
Q3 		– Sell
-14,158
Closed -$121K – 4704
2024
Q2 		$121K Sell
14,158
-51,040
-78% -$394K ﹤0.01% 3758
2024
Q1 		$518K Sell
65,198
-34,610
-35% -$371K ﹤0.01% 3026
2023
Q4 		$988K Buy
+99,808
New +$866K ﹤0.01% 2536
2023
Q3 		– Sell
-40,316
Closed -$134K – 4254
2023
Q2 		$134K Sell
40,316
-52,422
-57% -$189K ﹤0.01% 3310
2023
Q1 		$366K Buy
+92,738
New +$538K ﹤0.01% 2468
2022
Q4 		– Sell
-27,979
Closed -$101K – 3601
2022
Q3 		$101K Buy
+27,979
New +$119K ﹤0.01% 2794
2022
Q2 		– Sell
-83,555
Closed -$633K – 3380
2022
Q1 		$633K Buy
+83,555
New +$724K ﹤0.01% 1872

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Squarepoint's TNGX Position: Q1 2026 in Review

Squarepoint increased its Tango Therapeutics (TNGX) stake by 2.9% in Q1 2026, buying an estimated $69.3K and bringing the position to 178,915 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Squarepoint first reported a position in TNGX in Q1 2022 and has held it in 10 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Squarepoint held 178,915 shares of Tango Therapeutics worth $3.74M as of Q1 2026.
  • Squarepoint bought 4,979 Tango Therapeutics shares in Q1 2026, an estimated $69.3K.
  • Tango Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1725 holding.
  • Squarepoint first reported a position in Tango Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.